Patents by Inventor Naftali Kaminski

Naftali Kaminski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and Methods of Treating or Preventing Fibrotic Lung Diseases
    Publication number: 20230372275
    Abstract: The invention includes a method of preventing or treating a fibrotic lung disease in a subject, comprising administering to the subject a thyroid receptor ?-agonist. The invention further comprises compositions and kits comprising compositions useful within the invention.
    Type: Application
    Filed: April 14, 2023
    Publication date: November 23, 2023
    Inventors: Naftali Kaminski, Guoying Yu, Argyrios Tzouvelekis
  • Methods of Treating or Preventing Acute Respiratory Distress Syndrome
    Publication number: 20230364044
    Abstract: The invention includes a method of preventing or treating acute respiratory distress syndrome (ARDS) in a subject, comprising administering to the subject a thyroid hormone and/or a thyroid receptor ?-agonist.
    Type: Application
    Filed: January 13, 2023
    Publication date: November 16, 2023
    Inventors: Naftali Kaminski, Patty Lee, Guoying Yu, Yi Zhang
  • Compositions and methods of treating or preventing fibrotic lung diseases
    Patent number: 11660281
    Abstract: The present invention includes a method of preventing and/or treating a fibrotic lung disease in a subject. In certain embodiments, the method comprises administering to the subject a thyroid receptor ?-agonist. The invention further comprises compositions useful within the invention, as well as kits comprising compositions useful within the invention.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: May 30, 2023
    Assignee: YALE UNIVERSITY
    Inventors: Naftali Kaminski, Guoying Yu, Argyrios Tzouvelekis
  • MICRORNA-33 INHIBITORS AND USE THEREOF IN THE TREATMENT OF PULMONARY FIBROSIS
    Publication number: 20220364083
    Abstract: In one aspect, the present disclosure provides a microRNA-33 (miR-33) inhibitor comprising a peptide nucleic acid covalently bound to a pH low insertion peptide. In another aspect, the present disclosure provides a method of treating pulmonary fibrosis in a subject, the method comprising administering to the subject a therapeutically effective amount of the miR-33 inhibitor. In some embodiments, the pulmonary fibrosis is idiopathic pulmonary fibrosis.
    Type: Application
    Filed: May 13, 2022
    Publication date: November 17, 2022
    Inventors: Farida Ahangari, Naftali Kaminski, Carlos Fernandez-Hernando, Raman Bahal
  • BIOMARKERS FOR ASSESSING IDIOPATHIC PULMONARY FIBROSIS
    Publication number: 20220235417
    Abstract: Disclosed are methods and kits for evaluating predicting whether an individual IPF has slowly or rapidly progressive IPF.
    Type: Application
    Filed: March 29, 2021
    Publication date: July 28, 2022
    Applicants: The University of Chicago, The Board of Trustees of the University of Illinois, University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Imre Noth, Yong Huang, Jose David Herazo-Maya, Naftali Kaminski, Kevin Gibson, Joe G.N. Garcia
  • Biomarkers for assessing idiopathic pulmonary fibrosis
    Patent number: 10961582
    Abstract: Disclosed are methods and kits for evaluating predicting whether an individual IPF has slowly or rapidly progressive IPF.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: March 30, 2021
    Assignees: The University of Chicago, The Board of Trustees of the University of Illinois, University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Imre Noth, Yong Huang, Jose David Herazo-Maya, Naftali Kaminski, Kevin Gibson, Joe G. N. Garcia
  • 52-gene signature in peripheral blood identifies a genomic profile associated with increased risk of mortality and poor disease outcomes in idiopathic pulmonary fibrosis
    Patent number: 10896740
    Abstract: The clinical course of idiopathic pulmonary fibrosis (IPF) is difficult to predict. Described herein is a peripheral blood 52-gene expression signature useful to improve outcome prediction in IPF.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: January 19, 2021
    Assignee: Yale University
    Inventors: Naftali Kaminski, Jose D. Herazo-Maya
  • Methods of Treating or Preventing Acute Respiratory Distress Syndrome
    Publication number: 20210008020
    Abstract: The invention includes a method of preventing or treating acute respiratory distress syndrome (ARDS) in a subject, comprising administering to the subject a thyroid hormone and/or a thyroid receptor ?-agonist.
    Type: Application
    Filed: March 12, 2019
    Publication date: January 14, 2021
    Inventors: Naftali Kaminski, Patty Lee, Guoying Yu, Yi Zhang
  • Methods of treating or preventing fibrotic lung diseases
    Patent number: 10792265
    Abstract: The invention includes a method of preventing or treating a fibrotic lung disease in a subject, comprising administering to the subject a thyroid hormone by inhalation and/or aerosolization. The invention further comprises compositions and kits comprising compositions useful within the invention.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: October 6, 2020
    Assignee: Yale University
    Inventors: Naftali Kaminski, Argyrios Tzouvelekis, Guoying Yu
  • Compositions and Methods of Treating or Preventing Fibrotic Lung Diseases
    Publication number: 20200113863
    Abstract: The present invention includes a method of preventing and/or treating a fibrotic lung disease in a subject. In certain embodiments, the method comprises administering to the subject a thyroid receptor ?-agonist. The invention further comprises compositions useful within the invention, as well as kits comprising compositions useful within the invention.
    Type: Application
    Filed: June 26, 2018
    Publication date: April 16, 2020
    Inventors: Naftali Kaminski, Guoying Yu
  • METHODS OF TREATING OR PREVENTING FIBROTIC LUNG DISEASES
    Publication number: 20180369179
    Abstract: The invention includes a method of preventing or treating a fibrotic lung disease in a subject, comprising administering to the subject a thyroid hormone by inhalation and/or aerosolization. The invention further comprises compositions and kits comprising compositions useful within the invention.
    Type: Application
    Filed: January 31, 2018
    Publication date: December 27, 2018
    Inventors: Naftali KAMINSKI, Argyrios TZOUVELEKIS, Guoying YU
  • BIOMARKERS FOR ASSESSING IDIOPATHIC PULMONARY FIBROSIS
    Publication number: 20180320234
    Abstract: Disclosed are methods and kits for evaluating predicting whether an individual IPF has slowly or rapidly progressive IPF.
    Type: Application
    Filed: July 10, 2018
    Publication date: November 8, 2018
    Inventors: Imre Noth, Yong Huang, Jose David Herazo-Maya, Naftali Kaminski, Kevin Gibson, Joe G.N. Garcia
  • Biomarkers for assessing idiopathic pulmonary fibrosis
    Patent number: 10036069
    Abstract: Disclosed are methods are kits for evaluating predicting whether an individual IPF has slowly or rapidly progressive IPF.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: July 31, 2018
    Assignees: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, THE UNIVERSITY OF CHICAGO, THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Imre Noth, Yong Huang, Jose David Herazo-Maya, Naftali Kaminski, Kevin Gibson, Joe G. N. Garcia
  • 52-GENE SIGNATURE IN PERIPHERAL BLOOD IDENTIFIES A GENOMIC PROFILE ASSOCIATED WITH INCREASED RISK OF MORTALITY AND POOR DISEASE OUTCOMES IN IDIOPATHIC PULMONARY FIBROSIS
    Publication number: 20180101642
    Abstract: The clinical course of idiopathic pulmonary fibrosis (IPF) is difficult to predict. Described herein is a peripheral blood 52-gene expression signature useful to improve outcome prediction in IPF.
    Type: Application
    Filed: October 6, 2017
    Publication date: April 12, 2018
    Applicant: Yale University
    Inventors: Naftali Kaminski, Jose D. Herazo-Maya
  • Methods of treating or preventing fibrotic lung diseases
    Patent number: 9913819
    Abstract: The invention includes a method of preventing or treating a fibrotic lung disease in a subject, comprising administering to the subject a thyroid hormone by inhalation and/or aerosolization. The invention further comprises compositions and kits comprising compositions useful within the invention.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: March 13, 2018
    Assignee: Yale University
    Inventors: Naftali Kaminski, Argyrios Tzouvelekis, Guoying Yu
  • NOVEL METHODS OF TREATING OR PREVENTING FIBROTIC LUNG DISEASES
    Publication number: 20170105956
    Abstract: The invention includes a method of preventing or treating a fibrotic lung disease in a subject, comprising administering to the subject a thyroid hormone by inhalation and/or aerosolization. The invention further comprises compositions and kits comprising compositions useful within the invention.
    Type: Application
    Filed: June 11, 2015
    Publication date: April 20, 2017
    Inventors: Naftali KAMINSKI, Argyrios TZOUVELEKIS, Guoying YU
  • Marker Panels For Idiopathic Pulmonary Fibrosis Diagnosis And Evaluation
    Publication number: 20140335547
    Abstract: The present invention relates to the discovery that of a panel of serum or plasma markers may be used to diagnose Idiopathic Pulmonary Fibrosis (“IPF”) and distinguish this condition from other lung ailments. It further relates to the identification of markers associated with IPF disease progression.
    Type: Application
    Filed: May 14, 2014
    Publication date: November 13, 2014
    Applicants: Instituto Nacional De Enfermedades Respiratorias Ismael Cosio Villegas, United States Of America, Secretary, Dept. Of Health And Human Services, The University Of Chicago, University Of Pittsburgh - Of The Commonwealth System Of Higher Education
    Inventors: Naftali Kaminski, Kevin F. Gibson, Bernadette R. Gochuico, Thomas J. Richards, Ivan Rosas, Kazuhisa Konishi, Moises Selman, Jose David Herazo-Maya, Imre Noth
  • BIOMARKERS FOR ASSESSING IDIOPATHIC PULMONARY FIBROSIS
    Publication number: 20140323343
    Abstract: Disclosed are methods are kits for evaluating predicting whether an individual IPF has slowly or rapidly progressive IPF.
    Type: Application
    Filed: November 16, 2012
    Publication date: October 30, 2014
    Applicant: University of Chicago
    Inventors: Imre Noth, Yong Huang, Jose David Herazo-Maya, Naftali Kaminski, Kevin Gibson, Joe G.N. Garcia
  • Marker panels for idiopathic pulmonary fibrosis diagnosis and evaluation
    Patent number: 8846341
    Abstract: The present invention relates to the discovery that of a panel of serum or plasma markers may be used to diagnose Idiopathic Pulmonary Fibrosis (“IPF”) and distinguish this condition from other lung ailments. It further relates to the identification of markers associated with IPF disease progression.
    Type: Grant
    Filed: March 3, 2011
    Date of Patent: September 30, 2014
    Assignees: University of Pittsburgh—of the Commonwealth System of Higher Education, The University of Chicago, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas—D.F.
    Inventors: Naftali Kaminski, Kevin F. Gibson, Bernadette R. Gochuico, Thomas J. Richards, Ivan Rosas, Kazuhisa Konishi, Moises Selman, Jose David Herazo-Maya, Imre Noth
  • MMP activation peptide detection in biological samples
    Patent number: 8568996
    Abstract: A method is provided along with related reagent kits for aiding the diagnosis of IPF or other interstitial lung diseases, as well as for potential monitoring of disease progression or therapeutic response to treatment.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: October 29, 2013
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Jan Johannes Enghild, Naftali Kaminski, Tim D. Oury, Laura Voeghtly